This article identifies the factors that facilitate and inhibit the development, commercialization, and adoption of biosimilars and recommends modifications in program design that are likely to support the demonstration of the value of biosimilars for payers, providers, and patients.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
